At a glance
- Originator Nisshin Pharma
- Developer Kaken Pharmaceutical; Nisshin Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Sep 2000 Discontinued-I for Cancer in Japan (IV-injection)